Researchers at Penn State University are leading a multi-center phase II Big Ten Cancer Research Consortium study for adults with previously untreated, locally advanced pancreatic cancer that tests liposomal irinotecan in combination with FOLFOX, a chemotherapy regimen that includes oxaliplatin, leucovorin, and 5-fluorouracil.
Researchers hope to determine the disease control rate of this combination — the percentage of patients whose tumors respond to treatment or remain stable. The study could help determine if this novel approach could be used as a first-line treatment for locally advanced pancreatic cancer.
Liposomal irinotecan uses a tiny bubble called a liposome that is made of the same material as a cell wall. The liposome is filled with a drug called irinotecan that will circulate through a subject’s body for an extended period, which may result in a longer treatment effect and may help minimize harmful side effects of the drug on healthy tissue. Read More
September 24, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights a variety of activities and accomplishments across universities. From new cancer drugs, to grant awards and new methods of treatments, researchers stop at nothing to continue to fight against cancer. Read More
September 9, 2020: This month, the Big Ten Cancer Research Consortium highlights the University of Wisconsin Carbone Cancer Center as our featured member. UW Carbone member Elisavet Paplomata, MD, an assistant professor in the Department of Medicine, shares her research interests and expertise in breast and gynecologic cancers in this story, originally published by uwhealth.org.
At the Intersection of Breast and Gynecologic Cancers: Dr. Elisavet Paplomata
August 19, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights investigators focusing on breast cancer research and recent grants awarded to researchers and cancer centers across the Big Ten CRC. Read More
August 1, 2020: This month, the Big Ten Cancer Research Consortium highlights Masonic Cancer Center, University of Minnesota, as our featured member. Veronika Bachanova, MD, PhD, shares her research interests, and Jeffrey Miller, MD, discusses his research in natural killer (NK) cells.
Investigator Spotlight
Veronika Bachanova, MD, PhD, professor of medicine, Masonic Cancer Center, University of Minnesota Medical SchoolEducational background Medical School: Komenius University, Bratislava, Slovakia Residency: Henry Ford Hospital, Detroit, Mich. Fellowship: University of Minnesota, Minneapolis,... Read More
July 13, 2020: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights research on disparities when treating and diagnosing cancers, developments in cellular, genomic research, blood diseases, and big data, and ongoing growth at member cancer centers. Read More
July 1, 2020:Investigator SpotlightZeynep Madak-Erdogan, PhD, University of Illinois at Urbana-Champaign Educational background PhD: University of Illinois at Urbana-Champaign BS: Bilkent University, Ankara, Turkey Research interests I am the director of the Women’s Health, Hormones, and Nutrition lab at the University of Illinois at Urbana-Champaign. My research interests include the impact of nutrients and hormones on breast cancer outcomes, health disparities in African-American women with breast cancer, and the impact of estrogen receptor alpha and kinase signaling cross-talk on the development and progression of breast cancer. I am also... Read More
June 16, 2020: A Big Ten Cancer Research Consortium phase Ib study, led by the University of Michigan Rogel Cancer Center, will test the maximum tolerated dose and response rate of the PI3K alpha/delta inhibitor copanlisib in combination with the immunotherapy agents nivolumab and rituximab in adults with relapsed or refractory follicular or marginal zone indolent lymphoma. The study is now open to accrual at the University of Michigan. Follicular lymphoma is the second most common non-Hodgkin lymphoma (NHL), with approximately 15,000 cases diagnosed in the United States per year. Indolent lymphoma is a subtype of NHL that grows and spreads slowly in the lymphatic system. While advances in progression-free survival and overall... Read More
June 12, 2020: Monika D. Joshi, MD, MRCP, associate professor of medicine at Penn State Cancer Institute, was recently appointed to represent Penn State on the Big Ten Cancer Research Consortium (Big Ten CRC) Steering Committee. The committee is composed of one researcher from each member institution and meets regularly to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC. Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube